IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma

Huafang Jia, Xiaoli Xie, Long Wang, Lijuan Wang and Fengyuan Che

Department of Neurology, Linyi People's Hospital, Qingdao University, Qingdao 266071, Shandong, China
Central Laboratory, Linyi People's Hospital, Linyi 276000, Shandong, China

Correspondence should be addressed to Huafang Jia; 2021010086@qdu.edu.cn

Received 30 March 2022; Accepted 24 May 2022; Published 29 June 2022

Copyright © 2022 Huafang Jia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glioblastoma is the most malignant primary glioma. Conventional treatment methods that include surgery, radiotherapy, and chemotherapy have a limited curative effect on the tumor. With the deepening of molecular biology research, molecular targeted therapy has opened a new era of tumor therapy. Programmed death ligand 1 (PD-L1) has been proved to play a pivotal role in the tumor immune evasion process. Previous studies have confirmed the specific expression of PD-L1 in glioblastoma tissues and cells, but there are few studies on inflammation regulating PD-L1 in glioblastoma. In this study, real-time PCR, flow cytometry, and western blot were applied to detect PD-L1 in glioblastoma cells. Short hairpin RNA was used to knock down PD-L1 in glioblastoma cells. Cell counting kit-8 experiment and wound-healing assay were used to detect the proliferation and migration of glioblastoma cells. Here we demonstrated that PD-L1 was overexpressed in glioblastoma cells, and interferon-gamma (IFN-γ) induces PD-L1 in glioblastoma cells via activating p38/JNK/ERK signaling pathways. To summarize, PD-L1 promotes the occurrence and development of glioblastoma. IFN-γ counteracts the tumor-promoting effects mediated by PD-L1 in glioblastoma. IFN-γ regulates PD-L1 through multiple signaling pathways, but the total effect of IFN-γ-mediated inflammatory signals still need to be further explored in glioblastoma. PD-L1 enhances the proliferation and migration of glioblastoma cells by regulating CDK4, CDK6, MMP-2, and vimentin molecules. Most importantly, targeting PD-L1 can be applied in the treatment of glioblastoma. We speculate that IFN-γ may affect glioblastoma through other pathways, and we will continue to further explore the mechanisms in the future.

1. Introduction

Glioblastoma is one of the malignant brain tumors with the highest incidence, accounting for almost 25% of primary central nervous system tumors and 50% of adult glioma [1, 2]. At present, surgical resection and chemoradiotherapy are still the main treatment methods for glioblastoma, but the postoperative recurrence rate remains high because of its high invasiveness and invasive growth of tumor tissue [3]. Hundreds of clinical trials have been carried out for decades in glioblastoma. Nevertheless, the results of some large phase III international clinical trials show that various treatment methods have no significant effect on glioblastoma patients, and the curative effects of multiple preventive and therapeutic drugs are not ideal or have great toxic and side effects [4]. Therefore, the treatment of malignant glioma especially glioblastoma confronts great challenges. It is urgent to delve into new treatment schemes to curb the progress of glioblastoma, and further improve the prognosis of glioblastoma patients.

With the deepening of the research on tumor immune evasion, researchers gradually realize that the immune plays a significant part in preventing tumors and promoting the escape of tumor cells. Programmed death ligand 1 (PD-L1) produces inhibitory signals by binding with receptor molecules on T lymphocytes a member of immunosuppressive costimulatory molecules, which is essential for maintaining host self-tolerance and regulating innate and adaptive
immunity. Interferon-gamma (IFN-γ) is a cytokine with multiple activities, which has been recognized as significant pleiotropy in many inflammatory processes. In previous malignant tumor studies, the tumor microenvironment can advance tumor immune escape by releasing IFN-γ to stimulate PD-L1 in tumor cells [5, 6]. PD-1/PD-L1 inhibitors are widely available for tumor immunotherapy, but their mechanism in glioblastoma remains uncertain.

In this article, we confirmed that PD-L1 was expressed in glioblastoma cells. IFN-γ upregulated the expression of PD-L1 by activating p38/INK/ERK signaling pathways. PD-L1 knockdown suppressed the proliferation and migration of glioblastoma cells.

2. Materials and Methods

2.1. Cell Culture and IFN-γ Stimulation. Glioblastoma cell lines U251, TG-905, and A172 were cultured in the Dulbecco’s modified eagle medium (DMEM, Hyclone, USA) containing 10% fetal bovine serum (FBS; Gibco, USA) and 1% penicillin/streptomycin (Gibco, USA) at 37°C, 5% CO₂ conditions in the incubator. Fresh glioblastoma multiforme tissue, obtained from neurosurgical patients who seek medical advice in Linyi People’s Hospital, was washed and cut, digested with Trypsin (USA), and filtered out tissue fragments. Pelleted cells were cultured after centrifugation to obtain primary cells (PT-1 and PT-2). All the patients signed a written informed consent form. With DMSO as control, SB203580, SP600125, and U0126 (Calbiochem, La Jolla, CA) were added to the medium. IFN-γ (R & D Systems, USA) was diluted to 50 ng/mL with DMEM medium for cell stimulation after 30 min. Cells were detected at different time points.

2.2. Short Hairpin RNA (shRNA) and Transfection. Lentiviral-shRNA-PD-L1 and Lentiviral-shRNA-control were purchased from Santa Cruz Biotechnology (USA). Glioblastoma cells were categorized as wild type (wt) group, control-shRNA-transfected (shRNA-ctl) group, and PD-L1-shRNA-transfected (shRNA-PD-L1) group. U251, TG-905, A172, and PT-2 were cultured in six-well plates and transfected with shRNA-ctl and shRNA-PD-L1 after cell count reached 50% fusion rate according to the manufacturer’s protocol. Then we used puromycin (5 μg/mL) thrice to screen the cells.

2.3. RNA Extraction, cDNA Preparation, and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The RNA of glioblastoma cells was extracted with Trizol reagent (Invitrogen, USA). RNA was reverse transcribed into cDNA using the All-in-One First-Strand cDNA Synthesis Kit (GeneCopoeia, USA) according to the manufacturer’s protocol. Use the All-in-One qRT-PCR Mix (GeneCopoeia, USA) for qRT-PCR detection. The mRNA levels of PD-L1 were calculated by the $2^{-\Delta\Delta CT}$ method normalized to the Actin beta (ACTB) levels. The primers used in this research were PD-L1, 5′-GCTATGGTGTGCCGACTAC-3′ (forward) and 5′-CACTGCTTGTCAGATGACTTC-3′ (reverse); ACTB, 5′-TCATTCCAAATATGAGTGCGTTGTGTA-3′ (forward) and 5′-GCTATCACCTCCCCGTGTGTA-3′ (reverse).

2.4. Flow Cytometry Analysis. We used direct immunofluorescence of antibodies against PD-L1 to detect the expression of PD-L1 molecules on the cell surface. After being stained with antibodies for 30 min under the protection from the light condition, cells were resuspended in phosphate-buffered saline. Flow cytometry was performed using a FACS Canto. The data were analyzed by FlowJo software.

2.5. Cell Counting Kit-8 (CCK-8) Assay. Glioblastoma cells were cultured for 24, 48, and 72 h. The read absorbance value at 450 nm after CCK-8 (Bestbio, Shanghai, China) was put to cells.

2.6. Western Blot Analysis. We used a protein extraction kit (BestBio, Shanghai, China) to extract total protein and the total protein content was measured by the BCA method. Protein was isolated and prepared using 10% SDS-PAGE and PVDF membranes. The prepared membrane was blocked with 5% evaporated milk and a primary antibody (1:1000) was added and incubated overnight at 4°C. A secondary antibody (1:2000) was added and incubated with the membrane for 1 h after three washes with TBST buffer. Finally, membranes were exposed to a chemiluminescence imaging system after developing with ECL luminescent reagent. Antibodies against PD-L1 (e Bioscience, USA), GAPDH (Proteintech, USA), CDK4, CDK6, MMP-2 (Cell Signaling Technology, USA), and vimentin (Abcam, UK) were added.

2.7. Wound-Healing Assay. Glioblastoma cells were implanted in six-well plates until they reached 100% confluence. Then, the cell layers were scratched with the tip of the pipette (200 μL) and washed with PBS to remove the cell fragment. About 2 mL of serum-free DMEM medium was added to the six-well plates and incubated at 37°C in 5% CO₂. Samples were taken at different time points, and three scratches were randomly selected under the microscope to take photos. The results were measured by Image J software.

2.8. Statistical Analysis. All experimental data were performed using Graphpad Prism 8.0 software statistically. Data in every group were expressed with mean ± standard deviation (mean ± SD) and verified by three independent experiments. The difference was analyzed using t-test. $P < 0.05$ were defined as statistically significant.

3. Results

3.1. PD-L1 Was Expressed in Glioblastoma Cell and IFN-γ Enhances PD-L1 mRNA, Surface Protein, and Total Protein Expression in Glioblastoma Cells. To evaluate the expression of PD-L1 in human glioblastoma cells, we applied western blotting and flow cytometry to assess human glioblastoma
cell lines (U251, TG-905, and A172) and primary tumor cells separated from tissues of glioblastoma patients (PT-1 and PT-2). The results showed that the total protein (Figure 1(a)) and surface protein levels (Figure 1(b)) of PD-L1 were expressed in the glioblastoma cells. Furthermore, we further explored the regulatory mechanisms of IFN-γ (50ng/mL) induced PD-L1 expression in glioblastoma. IFN-γ induced the total protein levels (Figure 1(c)) of PD-L1 in U251, TG-905, and PT-2, and the effect is the most significant at 24 h. IFN-γ upregulated the surface protein levels (Figure 1(c)) expression of PD-L1 in U251, TG-905, A172, PT-1, and PT-2.

3.2. IFN-γ Regulates PD-L1 Expression via the p38/JNK/ERK Signaling Pathways. Next, we elucidated the mechanism of IFN-γ regulating PD-L1. After treatment with SB203580, SP600125, and U0126, we performed western blotting to investigate alterations in PD-L1, p38, JNK, and ERK. The results show that blocking p38 (Figure 2(a)), JNK (Figure 2(b)), and ERK (Figure 2(c)) signaling pathways can inhibit the upregulation of PD-L1 by IFN-γ.

3.3. PD-L1 Knockdown in Glioblastoma Cells. We knocked down PD-L1 expression in glioblastoma cells via transfection of shRNA-PD-L1. The knockdown efficiency at the mRNA level was significant when comparing the shRNA-PD-L1 group with the shRNA-ctl group and wt group (**P < 0.001, ***P < 0.001, **P < 0.01; Figure 3(a)). Compared with the shRNA-ctl group and wt group, the expression of PD-L1 protein in the shRNA-PD-L1 group decreased (Figure 3(b)). After being stimulated with IFN-γ, the expression level of PD-L1 mRNA increased in the three groups (**P < 0.001, ***P < 0.001, ***P < 0.001) by qRT-PCR (Figure 3(a)). Western blot confirmed that the expression of PD-L1 was elevated in three groups, but the expression level of PD-L1 in the shRNA-PD-L1 group was weaker than that in the shRNA-ctl and wt groups (Figure 3(b)).

3.4. PD-L1 Knockdown Inhibits Glioblastoma Cells Proliferation and Migration. We explored the effects of PD-L1 knockdown on glioblastoma cell proliferation and migration. These results of CCK8 assay showed that compared with the shRNA-ctl group, shRNA-PD-L1 inhibited the proliferation of U251 cells and PT-2 cells (Figures 4(a) and 4(b), ***P < 0.001). After 24 h of IFN-γ stimulation, the results show that there was no discernible difference in the proliferation of U251 cells (Figure 4(a)) and TG-905 cells (Figure 4(b)). A wound-healing assay was performed to examine PD-L1 in glioblastoma cell migration. The results show that there was no difference in the three groups’ cell

![Figure 1: PD-L1 expression in human glioblastomas.](image-url)
motility of U251 and TG-905 groups after 24 h. Compared with the shRNA-ctl group, the motility of U251 and TG-905 cells (Figure 5, \( P < 0.05 \)) in the shRNA-PD-L1 group decreased. After 24 and 48 h of IFN-\( \gamma \) stimulation, the results show that there was no obvious change in the migration of U251 and TG-905 cells (Figure 5).

3.5. PD-L1 Regulates CDK4, CDK6, MMP-2, and Vimentin Expression. To explore the specific mechanism of PD-L1 regulating glioblastoma cell proliferation and migration, we detected the expression of related protein molecules in U251 cells by using western blot. The results show that PD-L1 knocked down suppressed the expression of CDK4, CDK6, MMP-2, and vimentin. Compared with no IFN-\( \gamma \) stimulation, the expression levels of CDK4, CDK6, MMP-2, and vimentin in wt, shRNA-ctl, and shRNA-PD-L1 cells decreased after the addition of IFN-\( \gamma \) 48 h (Figure 6).

4. Discussion

Glioblastoma is the most invasive brain tumor, also known as glioblastoma multiforme. The high invasiveness of glioblastoma cells leads to tumor reappearance and poor prognosis [7]. At present, it is considered that surgery combined with chemotherapy or immunotherapy promotes overcoming drug resistance and improves the survival rate of glioblastoma patients [8]. Although temozolomide (TMZ), lomustine, carmustine, and bevacizumab already have Food and Drug Administration (FDA) approval to treat glioblastoma, their efficacy is very limited [9]. Most clinical trials show that drug resistance to glioma treatment remains a major obstacle, albeit great progress has been made in various cancer treatments [10]. In recent years, tumor molecular targeted therapy has become a research hotspot. However, the tumor immune molecular mechanisms driving glioblastoma remain largely elusive. Therefore, it is
Figure 3: Efficiency of PD-L1 knockdown. (a) PD-L1 mRNA expression in wt group and shRNA-ctl or shRNA-PD-L1 group for U251, TG-905, and PT-2 was detected by qRT-PCR before and after IFN-γ stimulation (*** P < 0.001, ** P < 0.01). (b) PD-L1 protein expression in wt, shRNA-ctl or shRNA-PD-L1 group for U251, TG-905, and PT-2 was detected before and after interferon stimulation.

Figure 4: PD-L1 knockdown inhibits glioblastoma cell proliferation. The proliferation capacity of U251 (a) and PT-2 (b) were demonstrated by the CCK8 assay. Compared with shRNA-ctl groups, shRNA-PD-L1 restrained the proliferation of U251 cells (A, *** P < 0.001) and PT-2 cells (B, *** P < 0.001). IFN-γ stimulation had no effect on the proliferation of U251 cells (A) and TG-905 cells (B).
significant to deeply explore the specific mechanism of the occurrence and development of glioblastoma, which is of great significance for the molecular targeted therapy of glioblastoma. PD-1/PD-L1 axis plays a crucial role in tumor immunity escapes, making it an effective target of antitumor immunity. PD-L1 inhibitors have been widely used in several tumor immunotherapy, but their mechanisms in glioma remain unclear. It is known that PD-L1 in many tumors has high expression, including lung cancer, colorectal cancer, gastric cancer, melanoma, leukemia, stromal tumor, multiple myeloma, esophageal, ovarian, pancreatic, renal cell carcinoma, oral squamous cell carcinoma, and nasopharyngeal carcinoma [11–18].

Previous researchers have detected abnormal expression of PD-L1 in human glioma specimens [19], and the expression level of PD-L1 in human glioma tissues was significantly higher than that in normal brain tissue around or far away from the tumor [20]. According to a study, the expression of PD-L1 was related to the grade and genotype of glioma [21]. Compared with isocitrate dehydrogenase wild type glioma, the expression of PD-L1 was lower in isocitrate dehydrogenase mutant glioma [22]. Now a study suggests that higher serum soluble PD-L1 and soluble PD-1 are present in patients with advanced tumors, which may be potential biomarkers for prognosis in glioma patients [23]. The changes of sPD-L1 can be measured in patients using

![Figure 5: PD-L1 knockdown inhibits glioblastoma cell migration.](image)

![Figure 6: Effects of PD-L1 knockdown or IFN-γ stimulation on the expression of CDK4, CDK6, MMP-2, vimentin, and GAPDH was tested by western blot in U251 cells.](image)
Initially, the researchers found that IFN-α cell apoptosis, tumor dormancy, and immune editing [30]. IFN-α responses [29]. IFN-α has been confirmed to induce tumor cell apoptosis, tumor dormancy, and immune editing [30]. Initially, the researchers found that IFN-α can enhance the killing effect of immune cells on the tumor by promoting Th1 cells differentiation and CTL cells activation, and prevent tumor cell proliferation and apoptosis by binding with IFN-α receptors. However, there is increasing evidence that IFN-α plays a related immunomodulatory role in two aspects [31]. IFN-α is the strongest cytokine regulating PD-L1. Therefore, exploring the mechanism of IFN-α regulating PD-L1 in tumorigenesis and development has potential clinical value. Earlier work has explored that IFN-α promotes the expression of PD-L1 in tumor cells through multiple signal pathways, including PI3K/AKT, JAK/STAT, and ERK/JAK [32–34].

We detected the signal pathway-related molecular proteins downstream of IFN-α. The results showed that IFN-α induces hyperphosphorylation of p38, JNK, and ERK. After inhibiting the activation of the signaling pathway with SB203580, SP600125, and U0126, PD-L1 protein expression in glioblastoma cells decreased significantly. The above results show that IFN-α upregulates PD-L1 expression via p38/JNK/ERK signaling pathways. IFN-α with p38/JNK/ERK signaling pathways may regulate PD-L1 and promote the molecular targeted therapy in glioblastoma. And unexpectedly, we found that IFN-α reduce the expression of CDK4, CDK6, MMP-2, and vimentin, but had no significant impact on the proliferation and migration of glioblastoma cells. The result makes us think deeply. IFN-α inhibits the expression of CDK4, CDK6, MMP-2, and vimentin after significantly upregulating the expression of PD-L1, while the tumor-promoting effect mediated by PD-L1 is also offset.

We speculate that these results may be related to the dual role of IFN-α in tumor immune regulation. A previous study on lung cancer has found that IFN-α inhibits proliferation by activating JAK2/STAT1. The antiproliferative role of IFN-α was enhanced by inhibiting PI3K and reduced PD-L1 expression [35]. Although studies have confirmed that IFN-α activates multiple downstream signaling pathways to participate in tumor immune regulation, the mechanism of these signaling pathways in tumor biological behavior is still unclear, and the intersection between these pathways is unknown. In the clinical trial of recombinant IFN-α in cancer treatment, the results showed that the number of patients who benefited was limited, and many patients had serious side effects [36]. Some scholars reported that patients with squamous cell carcinoma of the head and neck, gastric cancer, and metastatic melanoma who were effective against PD-1 had higher expression levels of IFN-α-related genes than ineffective patients [37]. IFN-α signature may be a predictive marker in the treatment of immune checkpoint inhibitors. IFN-α signaling in immune function and tumor immunity is still disputed.

We hypothesized that IFN-α activated antitumor-related signaling pathways while regulating PD-L1 and antagonized the tumor-promoting effect of PD-L1. It is already found that CDK2 and CDK4 play a part in the inhibition of tumor proliferation by IFN-α. In the mouse model, CDK4 and CDK6 knockout allowed the mice to survive [38]. After CDK2 knockout, CDK1 binds to Cyclin E to promote the completion of tumor cell division [39]. Therefore, we hypothesize that there may be compensatory or mutually regulatory effects between cytokines.

5. Conclusion

In this research, we identified that IFN-α upregulates the expression of PD-L1 in glioblastoma cells via activating p38/JNK/ERK signaling pathways. PD-L1 enhances the proliferation and migration of glioblastoma cells via regulating CDK4, CDK6, MMP-2, and vimentin molecules. Above all, targeting PD-L1 may be applied to the treatment of glioblastoma. IFN-α counteracts the tumor-promoting effect mediated by PD-L1 in glioblastoma. We speculate that IFN-α may affect glioblastoma through other pathways, and we will continue to further explore its mechanism in the future.

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Disclosure

Huafang Jia and Xiaoli Xie are the co-first authors.
Conflicts of Interest

The authors declare that they have no conflicts of interest regarding this work.

Authors’ Contributions

Huafang Jia and Xiaoli Xie contributed equally to this work.

References

[1] J. Y. Nam and J. F. De Groot, “Treatment of glioblastoma,” *Journal of Oncology Practice*, vol. 13, no. 10, pp. 629–638, 2017.
[2] H. Ohgaki, “Epidemiology of brain tumors,” *Methods in Molecular Biology*, vol. 472, pp. 323–342, 2009.
[3] P. Diamandis and K. Aldepe, “World health organization 2016 classification of central nervous system tumors,” *Neurologic Clinics*, vol. 36, no. 3, pp. 439–447, 2018.
[4] P. B. Dirks, M. R. Gilbert, E. C. Holland, E. A. Maher, and W. A. Weiss, “Translating basic science discoveries into improved outcomes for glioblastoma,” *Clinical Cancer Research*, vol. 26, no. 11, pp. 2457–2460, 2020.
[5] R. D. Dorand, J. Nhale, J. T. Myers et al., “CdK5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity,” *Science*, vol. 353, no. 6297, pp. 399–403, 2016.
[6] J. Liu, A. Hamrouni, D. Wolowiec et al., “Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-TRAF6- and MEK-dependent pathway,” *Blood*, vol. 110, no. 1, pp. 296–304, 2007.
[7] A. Vollmann-Zwerozen, V. Leidgens, G. Feliciello, C. A. Klein, and P. Hau, “Tumor cell invasion in glioblastoma,” *International Journal of Molecular Sciences*, vol. 21, no. 6, 1932 pages, 2020.
[8] J. Fleurence, M. Bahri, S. Fougeray et al., “Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside,” *International Journal of Cancer*, vol. 146, no. 2, pp. 424–438, 2020.
[9] E. Cruz Da Silva, M. C. Mercier, N. Etienne-Selloum, M. Dontenwill, and L. Choulier, “A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials,” *Cancers*, vol. 13, no. 8, 1795 pages, 2021.
[10] S. A. Artene, A. Turcu-Stiuloiu, M. E. Ciurea et al., “Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials,” *Scientific Reports*, vol. 8, no. 1, 11800 pages, 2018.
[11] Y. Zhou, J. Miao, H. Wu et al., “PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes,” *Oncotarget*, vol. 8, no. 31, pp. 51210–51223, 2017.
[12] F. Xu, L. Xu, Q. Wang, G. An, G. Feng, and F. Liu, “Clinical-pathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis,” *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 9, pp. 14595–14603, 2015.
[13] Y. Tang, Y. He, L. Shi et al., “Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma.” *Oncotarget*, vol. 8, no. 24, pp. 39001–39011, 2017.
[14] T. Qin, Y. D. Zeng, G. Qin et al., “High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer,” *Oncotarget*, vol. 6, no. 32, pp. 33972–33981, 2015.
[15] T. Nomi, M. Sho, T. Akahori et al., “Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer,” *Clinical Cancer Research*, vol. 13, no. 7, pp. 2151–2157, 2007.
[16] S. Kleeff, C. Posch, S. R. Barthel et al., “Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth,” *Cell*, vol. 162, no. 6, pp. 1242–1256, 2015.
[17] R. A. Droeser, C. Hirt, C. T. Viehl et al., “Clinical impact of programmed cell death ligand 1 expression in colorectal cancer,” *European Journal of Cancer*, vol. 49, no. 9, pp. 2233–2242, 2013.
[18] M. Ameratunga, K. Asadi, X. Lin et al., “PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC,” *PLoS One*, vol. 11, no. 4, Article ID 0153954, 2016.
[19] R. Yamamoto, M. Nishikori, T. Kitakawa et al., “PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma,” *Blood*, vol. 111, no. 6, pp. 3220–3224, 2008.
[20] M. F. Sammamed and L. Chen, “A paradigm shift in cancer immunotherapy: from enhancement to normalization,” *Cell*, vol. 175, no. 2, pp. 313–326, 2018.
[21] Y. Zhang, C. Pan, J. Wang et al., “Genetic and immune features of resectable malignant brainstem gliomas,” *Oncotarget*, vol. 8, no. 47, pp. 82571–82582, 2017.
[22] A. S. Berghoff, B. Kiesel, G. Widhalm et al., “Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma,” *Neuro-Oncology*, vol. 17, no. 8, pp. 1064–1075, 2015.
[23] S. Liu, Y. Zhu, C. Zhang et al., “Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients,” *Journal of Medical Biochemistry*, vol. 39, no. 4, pp. 444–451, 2020.
[24] M. J. Mair, A. Ilhan-Mutlu, S. Rajendra et al., “Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma,” *Cancer Immunology, Immunotherapy*, vol. 70, no. 12, pp. 3643–3650, 2021.
[25] X. C. Ding, L. L. Wang, X. D. Zhang et al., “The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia,” *Journal of Hematology & Oncology*, vol. 14, no. 1, 92 pages, 2021.
[26] W. Dang, J. Xiao, Q. Ma et al., “Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia,” *Brain Tumor Pathology*, vol. 38, no. 3, pp. 189–200, 2021.
[27] J. Zhou, X. Pei, Y. Yang et al., “Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma,” *I Immunother Cancer*, vol. 4, no. 4, Article ID 001937, 2021.
[28] X. Y. Qiu, D. X. Hu, W. Q. Chen et al., “PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation,” *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1864, no. 5, pp. 1754–1769, 2018.
[29] J. L. Mendoza, N. K. Escalante, K. M. Jude et al., “Structure of the IFNγ receptor complex guides design of biased agonists,” *Nature*, vol. 567, no. 7746, pp. 56–60, 2019.
[31] M. Mandai, J. Hamanishi, K. Abiko, N. Matsumura, T. Baba, and I. Konishi, "Dual faces of IFNγ in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity," *Clinical Cancer Research*, vol. 22, no. 10, pp. 2329–2334, 2016.

[32] W. Xue, W. Li, T. Zhang et al., "Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-specific JAK-STAT pathway," *OncoTargets and Therapy*, vol. 12, pp. 2079–2088, 2019.

[33] T. Yokosuka, M. Takamatsu, W. Kobayashi-Imanishi, A. Hashimoto Tane, M. Azuma, and T. Saito, “Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2,” *Journal of Experimental Medicine*, vol. 209, no. 6, pp. 1201–1217, 2012.

[34] X. Zhang, Y. Zeng, Q. Qu et al., “PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer,” *International Journal of Clinical Oncology*, vol. 22, no. 6, pp. 1026–1033, 2017.

[35] Y. Gao, J. Yang, Y. Cai et al., "IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling," *International Journal of Cancer*, vol. 143, no. 4, pp. 931–943, 2018.

[36] M. R. Zaidi, "The interferon-gamma paradox in cancer," *Journal of Interferon and Cytokine Research*, vol. 39, no. 1, pp. 30–38, 2019.

[37] M. Ayers, J. Lunceford, M. Nebozhyn et al., "IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade," *Journal of Clinical Investigation*, vol. 127, no. 8, pp. 2930–2940, 2017.

[38] K. Kakimi, H. Matsushita, A. Hosoi, M. Miyai, and O. Ohara, "CTLs regulate tumor growth via cytostatic effects rather than cytotoxicity: a few T cells can influence the growth of many times more tumor cells," *OncoImmunology*, vol. 4, no. 3, Article ID 970464, 2015.

[39] J. Pogoriler, K. Millen, M. Utset, and W. Du, "Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation," *Development*, vol. 133, no. 19, pp. 3929–3937, 2006.